Revenue Breakdown
Composition ()
No data
Revenue Streams
Vertex Pharmaceuticals Inc (VRTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is TRIKAFTA, accounting for 86.3% of total sales, equivalent to $2.65B. Other significant revenue streams include ALYFTREK and Other CF products. Understanding this composition is critical for investors evaluating how VRTX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Vertex Pharmaceuticals Inc maintains a gross margin of 85.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.60%, while the net margin is 37.34%. These profitability ratios, combined with a Return on Equity (ROE) of 22.54%, provide a clear picture of how effectively VRTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, VRTX competes directly with industry leaders such as BMY and SNY. With a market capitalization of $126.21B, it holds a significant position in the sector. When comparing efficiency, VRTX's gross margin of 85.39% stands against BMY's 65.34% and SNY's 68.80%. Such benchmarking helps identify whether Vertex Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
